The Defence Research and Development Organisation (DRDO), which developed 2 -Deoxy-D-Glucose (2-DG), a drug used for the treatment of COVID-19 patients, has called for Express of Interest (EOI) to transfer the technology to Indian pharmaceutical industries for production.
The 2-DG is developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of DRDO, in collaboration with Dr Reddy’ Laboratories.
The third phase trials of 2-DG began in January, while the phase trials were conducted over three month period between June and September last year and involved 110 patients.
The DCGI had granted permission in May last year to Dr Reddy’s Laboratories for conducting a clinical trial of 2 DG for “acute treatment of moderate to severe Covid-19 patients.”
The government has recently launched 2-DG as an anti -Covid-19 therapeutic application of the drug 2-Deoxy-D-glucose (2-DG).
Patients treated with 2-DG have shown negative RT-PCR in COVID-19 patients.
It is proposed to offer Transfer of Technology (ToT) of 2-DG to Indian Pharmaceutical industries for production on the basis of some criteria. Drug License to manufacture Active Pharmaceutical Ingredient (API) from Drug Licensing Authorities.
The application for Express of Interest in up to 17th June 2021 and only up to 15 industries will be scrutinised by a Technical Assessment Committee (TAC) on the basis of capabilities, technical handholding capability of DRDO and on “First Come First Served Basis”.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
Source link
